FCF Healthcare & Life Sciences Venture Capital Monitor – USA – 02/2024 published - FCF Fox Corporate Finance GmbH

FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – USA – 02/2024”.

The Monitor is a monthly published overview of venture capital trends in the US Healthcare & Life Sciences sector.

As of the end of February 2024 we identify the following current VC trends in the United States:

• Total Healthcare & Life Sciences funding has reached EUR 5,224m
• Biotech received 58% of the total investment volume (EUR 3,040m) with oncology being the leading indication (30%)
• In February Areteia Therapeutics secures the highest transaction volume with EUR 392m, followed by Freenome with EUR 235m and BioAge with EUR 178m
• Premji Invest (United States) is the most active investor (by deal volume), followed by Novo Holdings (Denmark) and Sands Capital (United States)

To access the full report, please click here.